[Cardiotoxicity of 5-fluorouracil].
5-fluorouracil (5FU) is a largely employed antimetabolite, responsible for several well-known toxicities like hand-foot syndrome, diarrhoea, mucositis or leucopenia. Cardiotoxicity of 5-FU is known but uncommon and usually not life-threatening. The incidence has varied from 1.5 and 18%. The physiopathology is controversial, although more recent data suggest a myocardial toxicity. Clinical presentation include chest-pain, cardiac arrythmia, myocardial infarction or global cardiac failure. Electrocardiographic features are usually aspecific, with ischemic signs. The main treatment is to stop the 5-FU infusion and to introduce symptomatic cardiologic treatment. Although the prognosis is good, the mortality ranges between 2.2 and 13% in case of symptomatic cardiotoxicity. Secondary prophylaxis remains controversial.
Teixeira
Luis
L
Service de Médecine Interne et Oncologie Médicale, Hôpital Saint-Antoine, Paris, 184, rue du Faubourg Saint-Antoine, 75571 Paris Cedex 12.
Barry
Sonia
S
Debourdeau
Philippe
P
Cohen
Ariel
A
Tournigand
Christophe
C
D000964:Antimetabolites, Antineoplastic / Q000009:adverse effects*; D000069287:Capecitabine; D003328:Coronary Thrombosis / Q000139:chemically induced; D003331:Coronary Vessels / Q000187:drug effects; D003841:Deoxycytidine / Q000009:adverse effects / Q000031:analogs & derivatives*; D004562:Electrocardiography; D005472:Fluorouracil / Q000009:adverse effects*; D006321:Heart / Q000187:drug effects*; D006331:Heart Diseases / Q000139:chemically induced* / Q000628:therapy; D006801:Humans; D009205:Myocarditis / Q000139:chemically induced
D000964:Antimetabolites, Antineoplastic; D003841:Deoxycytidine; D000069287:Capecitabine; D005472:Fluorouracil